Мегейс®

General characteristics. Structure:

Active ingredient: 160 mg of megestrol of acetate.

Excipients: lactose, cellulose microcrystallic, povidone, kremiiya dioxide colloid, carboxymethylstarch of sodium, magnesium stearate.

Pharmacological properties:

Pharmacodynamics. Мегейс (megestrol) is synthetic progestogen. The exact mechanism of antineoplastic effect of drug of Megeys at a carcinoma of an endometria remains to unknown. It is considered that action is connected with existence of the anti-luteinizing effect which is implemented through a hypophysis. There is an instruction on the local effect of megestrol gained at direct administration of progestogens in a cavity of the uterus.

Antineoplastic effect of drug at a breast cancer and the mechanism by means of which drug is effective at anorexia and a cachexia are also unknown. Increase in body weight at reception of megestrol of acetate is connected with increase in appetite and increase in mass of fatty tissue and all organism in general.

Pharmacokinetics. Concentration in plasma depend on drug inactivation degree in a GIT and in a liver what mobility of an intestinal path, intestinal microflora, simultaneous use of antibiotics, body weight, a diet and a functional condition of a liver can influence.

Only about 5-8% of the dose of megestrol of acetate entered into an organism are the share of metabolites. The main ways of release of drug from a human body is allocation by kidneys (on average about 66%) and intestines (on average about 20% of the entered dose). That part of the entered dose which is not found in urine and Calais can be allocated through respiratory system and collect in fatty tissue.

Indications to use:

— palliative treatment of a widespread breast cancer or endometrial cancer;
— treatment of anorexia or loss of weight at malignant new growths or acquired immunodeficiency syndrome.

Route of administration and doses:

Inside. Definition of efficiency of use of drug requires, at least, two months of continuous treatment.

Breast cancer: 160 mg a day (once or in stages).

Endometrial cancer: 80-320 mg a day (once or in stages).

Anorexia or loss of body weight: the single daily dose makes 400-800 mg.

Aged patients: correction of a dose is not required.

Features of use:

Treatment by Megeys should be carried out under observation of the specialist having experience of use of chemotherapeutic treatment.

Against the background of therapy by Megeys and at least within 3 months later it is necessary to use reliable methods of contraception.

Side effects:

Increase in body weight is frequent effect at use of drug of Megeys for patients with cancer of a mammary gland or an endometria and is a consequence of the increased appetite.

Thromboembolism. It was reported about thromboembolism cases, including thrombophlebitis and an embolism of a lung.

Other side effects. The nausea, vomiting, hypostases and blood allocations from a cavity of the uterus which are not connected with periods are noted approximately at 1-2% of patients. It was reported about existence at patients of an asthma, pains, heart failure, a hypertension, inflows, changes of mood, cushingoid signs on a face, temporary activation of development of a tumor (in absence or in the presence of a hypercalcemia), a hyperglycemia, an alopecia, a syndrome of a carpal tunnel, diarrhea, a lethargy, skin rashes.

It was reported about development of the morbid conditions connected with disturbance of functioning of pituitary and adrenal system: intolerance of glucose, emergence of a diabetes mellitus and an aggravation of the available diabetes mellitus with decrease in tolerance to glucose and Cushing's syndrome. In rare instances at patients soon after the treatment termination drug MEGEYS observed clinical signs of adrenal insufficiency. It must be kept in mind a possibility of suppression of function of adrenal glands at all patients accepting drug for a long time and also after drug withdrawal. In such cases shock doses of glucocorticoids as replacement therapy can be shown.

Contraindications:

• hypersensitivity to the megestrol or any other substance which is a part of drug;
• as diagnostic test on pregnancy;
• pregnancy and period of feeding by a breast
• age up to 18 years (efficiency and safety are not established).

With care of Megeys it is necessary to apply at patients with thrombophlebitis in the anamnesis.

Overdose:

In clinical trials drug was used in doses to 1600 mg/day within 6 months and more. Any acute toxic effects were not revealed.

In case of overdose treatment has to have symptomatic character.

Storage conditions:

To store at a temperature not above 25 °C. To store in the place, unavailable to children. A period of validity - 3 years. Not to use drug after the expiry date specified on packaging.

Issue conditions:

According to the recipe

Packaging:

Tablets on 160 mg. On 30 tablets in the glass bottle of a dark stack corked by a polypropylene cover. 1 bottle together with the application instruction placed under the label of a bottle in a pack cardboard.